



FOUNDATION FUNDING OPPORTUNITIES: SEP 25, 2020

Please contact Corporate & Foundation Relations in the Office of Development at devcfr@mgh.harvard.edu if you wish to submit a proposal in response to any of these opportunities. Note that proposals are still routed through the standard InfoEd/Research Management process.

Please be aware that any grant that brings in less than **15% in indirect costs (IDC)** will need to be supplemented up to the 15% equivalent by existing investigator or departmental sundry funds. Resolution of this issue must occur prior to submitting a proposal. Training fellowships from foundations, public charity, and non-profit organizations are excluded from this minimum IDC requirement.

**Have you updated your MGH Researcher profile?
Go to <https://researchers.mgh.harvard.edu/> today!**

1. Grants for Parkinson's Research, Aligning Science Across Parkinson's (ASAP)/ Milken Institute

The Aligning Science Across Parkinson's (ASAP) Initiative invites applications to join the ASAP Collaborative Research Network, an effort to support international, multidisciplinary, multi-institutional research teams to address key knowledge gaps in the basic disease mechanisms that contribute to PD development and progression. Applications that focus primarily on Circuitry and Brain-body Interactions, inclusive of genetic and neuro-immune contributors to disease, will be considered.

Eligibility requirements (partial list):

- Core Leadership – Each Team must consist of a minimum of three (3) to a maximum of five (5) PIs. A Coordinating Lead PI must be appointed for each Team, who will be responsible for overall project management and reporting to ASAP/MJFF staff. Team structure and management is discussed in further detail below.
- Career Stage & Disciplines Represented – We require the Core Leadership for each Team to consist of at least one (1) early career investigator in the position of Co-I, and for there to be at least two (2) different disciplines represented on each Team.
- Institutions – There must be a minimum of two (2), but no more than five (5) participating institutions represented by the Team.

Citizenship: Unrestricted

Award Amount: Up to \$9 million paid over 3 years



Do you want to learn more about identifying external funding opportunities? Please [click here](#) to request a research consultation with **Amy Robb** or see ECOR's website for information on the [Pivot database](#).

Indirect Costs: 15%

Preproposal Deadline: Dec 11, 2020

(Invited) Proposal Deadline: Apr 13, 2021

Website: <https://parkinsonsroadmap.org/funding-opportunities/>

2. Drug Development Program, Alzheimer's Drug Discovery Foundation (ADDF)

The goal of this RFP is to develop therapeutics for Alzheimer's disease and related dementias. This RFP focuses on building preclinical evidence in animal models and on advancing lead molecules to the clinical candidate selection stage. The proposed studies should have a high probability of reaching IND-enabling studies within two years.

Specifically, the Drug Development RFP supports:

- Preclinical pharmacokinetics, pharmacodynamics, target engagement, and preliminary rodent tolerability
- In vivo efficacy or proof-of-concept studies
- Please note: IND-enabling work and clinical trials are supported through the Program to Accelerate Clinical Trials (PACT) RFP

The ADDF is interested in small molecules and biologics (e.g. antibodies, peptides, gene therapies). Both novel programs and repurposing/repositioning of approved or clinically safe therapies from other disease indications are appropriate for this RFP.

Current target areas of interest include:

- Epigenetics
- Inflammation
- Mitochondria & metabolic function
- Neuroprotection
- Proteostasis
- Synaptic activity and neurotransmitters
- Vascular function
- Other aging target (e.g. senescent cells)
- Other novel targets or pathways that are supported by compelling evidence demonstrating a rational biological connection to the disease process

Citizenship: Unrestricted

Award Amount: \$600,000 for 1 year

Indirect Costs: None

LOI Deadline: Oct 9, 2020

(Invited) Full Proposal Deadline: Nov 6, 2020

Website: <https://www.alzdiscovery.org/research-and-grants/funding-opportunities/drug-development-program>

3. Neuroimaging and CSF Biomarker Development Program, Alzheimer's Drug Discovery Foundation (ADDF)

The aim of this RFP is to develop biomarkers for which there is a clear clinical need in Alzheimer's disease and related dementias.

The ADDF focuses on supporting drug development for Alzheimer's and related dementias and the biomarker tools that aid in this process. This RFP prioritizes biomarker programs that define a specific use and have potential for commercial and clinical translation, with an emphasis on clinical trials (See the Evaluation section below). The RFP supports advancement of neuroimaging and CSF biomarkers that can do one or more of the following:

- **Demonstrate target engagement for novel therapeutics**
Biomarkers that can serve as direct measures of target engagement for novel drugs in clinical development. High priority will be given to projects advancing biomarkers that can be used as specific companion biomarkers for therapies currently in the development pipeline. Identification of such therapies strengthens an application.
- **Detect signs of disease earlier and monitor progression**
Programs developing sensitive biomarkers that can detect disease earlier than currently available biomarkers. This includes biomarkers that can predict and monitor conversion from cognitively healthy to mild cognitive impairment (MCI) or MCI to Alzheimer's disease. We also seek prognostic markers that can predict rates of cognitive decline.
- **More accurately diagnose and distinguish between dementia subtypes**
Many types of dementia can present with similar clinical features, and patients often show overlapping pathologies. At present, it is challenging to distinguish between dementia subtypes and proteinopathies. Biomarkers that can distinguish between subtypes and stratify patients in clinical trials are of high priority.

Citizenship: Unrestricted

Award Amount: \$600,000 for 1 year

Indirect Costs: None

LOI Deadline: Oct 9, 2020

(Invited) Full Proposal Deadline: Nov 6, 2020

Website: <https://www.alzdiscovery.org/research-and-grants/funding-opportunities/biomarkers>

4. Prevention Beyond the Pipeline, Alzheimer's Drug Discovery Foundation (ADDF)

The ADDF seeks to support comparative effectiveness research, prevention clinical trials, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline.

Specifically, the Prevention Beyond the Pipeline RFP supports:

1. **Studies Leveraging the Consortium of Cohorts for Alzheimer's Prevention Action (CAPA):** Epidemiological studies contribute unmatched information on whether the risk of dementia or cognitive decline may be influenced by long-term exposure to specific

foods or supplements. However, high-powered studies are needed, ideally with dose, duration, and responder profiles, in order to translate epidemiological research into actionable interventions for testing. Through the CAPA Consortium, the ADDF funds collaborative analyses on dementia prevention using a minimum of five longitudinal cohorts, either harmonized or analyzed through parallel analysis of cohorts using a shared analysis script.

2. **Comparative Effectiveness Research:** For many health conditions, physicians have a choice of clinically equivalent drugs. Some of these drugs are being investigated for repurposing to treat Alzheimer's or related dementias, due to potential disease-modifying properties that go beyond the treatment of their approved disease indication. The ADDF will consider funding research to generate an evidence base on whether choices in the routine clinical care of pre-existing conditions could protect from dementia. Priority will be given to the comparison of drugs that are otherwise clinically equivalent for the pre-existing condition. Methods may include randomized trials or epidemiology.
3. **Studies of Cognitive Decline and Cognitive Reserve:** Cognitive decline through aging and health conditions has been linked to an increased risk of dementia. The ADDF will consider funding programs to prevent and treat these conditions, including cognitive aging, menopause-related cognitive symptoms, postoperative delirium and postoperative cognitive decline, mild and/or repetitive traumatic brain injury, and chemotherapy-induced decline. Methods may include epidemiology or clinical trials. For clinical trial proposals, please see below detailed instructions and priorities under "Funding Priorities for Clinical Trial Proposals" and "Evaluation of Clinical Trial Proposals".

Citizenship: Unrestricted

Award Amount:

- \$50,000-\$100,000 for epidemiological analyses based on scope of research
- Up to \$3 million for clinical trials based on stage and scope of research
- For studies requiring additional support, co-funding from other funding agencies or investors is encouraged

Indirect Costs: None

LOI Deadline: Oct 9, 2020

(Invited) Full Proposal Deadline: Nov 6, 2020

Website: <http://www.alzdiscovery.org/research-and-grants/funding-opportunities/prevention-beyond-the-pipeline>

5. Program to Accelerate Clinical Trials (PACT), Alzheimer's Drug Discovery Foundation (ADDF)

The goal of this RFP is to increase the number of innovative pharmacologic interventions tested in clinical studies for Alzheimer's disease and related dementias. This includes novel, repurposed, and repositioned drugs as well as natural products.

Specifically, the PACT RFP supports:

Early-stage human clinical trials:

- Phase 1 single ascending dose and multiple ascending dose studies
- Biomarker-based proof-of-concept or proof-of-mechanism studies. These studies can validate novel molecular targets in humans and de-risk novel therapeutic approaches earlier in clinical development by assessing the potential efficacy of therapeutic interventions using pharmacodynamic outcomes.

Regulatory studies:

- Non-GLP and GLP pharmacology and toxicology studies, pre-formulation, and GMP manufacture required for investigational new drug (IND) and clinical trial authorization (CTA) preclinical packages. Funding is available for preparation of traditional and exploratory IND applications.
- Long-term toxicology studies to enable longer-term dosing in phase 2 trials
- GMP manufacturing and testing of clinical grade drug required to move into phase 2 or phase 3 trials

Citizenship: Unrestricted

Award Amount: \$3 million

LOI Deadline: Oct 9, 2020

(Invited) Full Proposal Deadline: Nov 6, 2020

Website: <https://www.alzdiscovery.org/research-and-grants/funding-opportunities/pact>

6. NBF Scientific Research Grants Program, American Association of Blood Banks (AABB)/ National Blood Foundation (NBF)

For over 30 years, the NBF has awarded over \$9 million to early-career investigators through its Scientific Research Grants Program. Grants are awarded for investigator-initiated original research in disciplines that impact transfusion medicine, cellular therapies or related sciences. Priority in awarding grants will be given to innovative, new projects.

Research content areas eligible for the grant program include the following:

- Immunology
- Hematology
- Immunohematology
- Infectious Diseases
- Cellular Therapies
- Patient Blood Management

An application fee of \$160 must accompany the application unless the primary investigator is an AABB individual member.

Eligibility requirements (partial list):

- An early-stage investigator is a new investigator who has completed a terminal research degree or medical residency - whichever date is later - within 10 years of the grant application deadline and has not yet been awarded a substantial research grant (i.e. NIH R01).

Citizenship: Unrestricted

Award Amount: \$75,000

Indirect Costs: None

Application Deadline: Dec 1, 2020

Website: <http://www.aabb.org/research/nbf/Pages/grantapplication.aspx>

7. Pilot Grant for Basic Science Research, Association for Frontotemporal Degeneration (AFTD)

AFTD Pilot Grants provide seed funding for innovative research projects in the preliminary stages of development, with an emphasis on early-career investigators in the process of establishing an independent research program. Projects funded through the Pilot Grant program are intended to generate data to support a follow-on grant application to the NIH, another public agency or a nonprofit organization.

Basic Science Pilot Grants - These grants support projects focused on the neurobiological mechanisms underlying FTD.

Eligibility requirements (partial list):

- New or early-stage investigators in the process of establishing an independent research program who have a faculty appointment or are serving a medical residency at an academic institution, teaching hospital, or other not-for-profit research institution
- Postdoctoral fellows cannot be Pilot Grant PIs, unless confirmation of a faculty appointment that will start within 3 months of the beginning of the funding period

Citizenship: Unrestricted

Award Amount: \$60,000 for 1 year

Indirect Costs: None

Application Deadline: Oct 9, 2020

Website: <https://www.theaftd.org/for-researchers/funding-opportunities/aftd-pilot-grants/>

8. Well-Being in FTD Pilot Grant, Association for Frontotemporal Degeneration (AFTD)

COVID!

AFTD Pilot Grants provide seed funding for innovative, early-stage research projects with the potential to increase understanding and improve the diagnosis or treatment of frontotemporal degeneration (FTD) across the full spectrum of FTD disorders: behavioral variant FTD, primary

progressive aphasia, progressive supranuclear palsy, corticobasal syndrome, and FTD-ALS. Pilot Grant-funded projects are intended to generate data that will support follow-on funding applications to the National Institutes of Health or other public or private agencies. The Well-Being in FTD Pilot Grant supports projects that seek to develop non-pharmacological, evidence-based interventions for improving daily quality of life for people living with FTD and their families, mitigating caregiver burden, or advancing person-centered approaches to FTD care in out-of-home settings. Proposals that focus on strategies to support telemedicine or assist caregivers in meeting the unique challenges imposed by the emergence of COVID-19 are especially encouraged.

Eligibility requirements (partial list):

- New or early-stage investigators in the process of establishing an independent research program who have a faculty appointment or are serving a medical residency at an academic institution, teaching hospital, or other not-for-profit research institution
- Postdoctoral fellows cannot be Pilot Grant PIs, unless confirmation of a faculty appointment that will start within 3 months of the beginning of the funding period

Citizenship: Unrestricted

Award Amount: \$60,000 for 1 year

Indirect Costs: None

Application Deadline: Oct 2, 2020

Website: <https://www.theaftd.org/for-researchers/funding-opportunities/aftd-pilot-grants/>

9. Inflammatory Bowel Disease (IBD) Innovator Awards, Kenneth Rainin Foundation

At the Rainin Foundation, we support high-risk research and challenge investigators to push boundaries to advance our goal of predicting and preventing Inflammatory Bowel Disease (IBD). Through the Innovator Awards, we invest in new and veteran IBD researchers alike and embrace novel, untested ideas. Our funding interests span the spectrum of basic, translational and clinical science.

To date, we have funded the following areas through Innovator Awards:

- Bioengineering
- Diet and Nutrition
- Epithelial Cell/Molecular Biology
- Fecal Microbiota Transplant
- Immunity and Inflammation
- Microbiome
- Therapeutic Development and Delivery

Citizenship: Unrestricted

Award Amount: \$150,000 for 1 year

Indirect Costs: 10%

LOI Deadline: Oct 19, 2020

(Invited) Full Proposal Deadline: Feb 8, 2021

Website: <http://krfoundation.org/health/innovator-awards/>

10. Bridge Funding Awards, Marsha Rivkin Center for Ovarian Cancer Research

The purpose of Bridge Funding is to allow researchers to produce data needed to substantiate their proposal resubmission to federal funding agencies for a promising new research project. The Bridge Funding Awards provides interim funding to researchers who have submitted an R01, R21, K08, K23, or K99 proposal to the National Institutes of Health (NIH) or an original proposal to the Department of Defense (DoD) pertaining to ovarian cancer and who have not received, but were close to, a fundable score. Investigator-initiated projects in all areas of ovarian cancer research are eligible. Special consideration will be given to research that has clinical applicability.

Eligibility requirements (partial list):

- Investigators at all levels are encouraged to apply. Unfunded first submission NIH R01, R21, K08, K23, and K99 proposals (no A1 or A2 proposals) as well as original DoD proposals are eligible for consideration. NIH proposals must have scored in the 19th percentile or lower, and DoD proposals must have scored less than 1.9. Proposals must have received their agency score within the past nine months. Proposals must require at least six months of additional research work prior to resubmission.

Citizenship: Unrestricted

Award Amount: \$30,000

Indirect Costs: None

Application Deadline: Oct 15, 2020

Website: <https://www.rivkin.org/research/grants/bridge-funding-awards/>

11. Pilot Study Awards, Marsha Rivkin Center for Ovarian Cancer Research

Investigators often struggle to find funding for innovative approaches to scientific questions because their new ideas may not yet be in the scientific mainstream. Each year we support multiple pilot studies to pave the way for new avenues of ovarian cancer research and to expand our understanding of the disease.

Citizenship: Unrestricted

Award Amount: \$75,000 paid over 2 years

Indirect Costs: None

Application Deadline: Dec 1, 2020

Website: <https://www.rivkin.org/research/apply/>

12. Scientific Scholar Award, Marsha Rivkin Center for Ovarian Cancer Research

The Rivkin Center Scientific Scholar Award is intended to assist promising laboratory and clinical scientists in pursuing a career as an independent investigator in ovarian cancer research. Research funding for ovarian cancer is comparatively low, which discourages talented laboratory scientists and physicians from directing their careers toward ovarian cancer. The Scientific Scholar Award provides the funds for the best and brightest minds to have an opportunity to begin a career in ovarian cancer research.

The program will strive to support the scientific growth and academic success of awardees. The goal is to attract junior investigators as well as established investigators into ovarian cancer research and to develop their potential as leaders. The Scientific Scholar Award program will produce leaders in multiple areas of ovarian cancer research.

Eligibility requirements (partial list):

- Potential candidates will have an MD, PhD, or equivalent degree with career goals focused on ovarian cancer.
- Clinicians will have completed their residency.
- Candidates should be at the post-doc/fellow, instructor, research assistant, or assistant professor level with no more than 3-4 years in any of these positions.
- Established, outstanding scientists without prior focus in ovarian cancer but looking to focus in this disease area are also encouraged to apply.
- Foreign and non-resident post-docs are not excluded from applying for the Scientific Scholar Award. However, commitment from a mentor for the duration of the project is required to accompany the letter of intent.

Citizenship: Unrestricted

Award Amount: \$120,000 paid over 2 years

Indirect Costs: None

Application Deadline: Dec 1, 2020

Website: <https://www.rivkin.org/research/grants/scientific-scholar-awards/>

13. Research Infrastructure Program, Massachusetts Life Sciences Center **NEW!**

The design of the Research Infrastructure program (formerly known as the Open or Competitive Capital Program) is to provide grants for capital projects that support the life sciences ecosystem in Massachusetts by enabling and supporting life sciences research and development in the Commonwealth.

Citizenship: United States

Award Amount: \$1.5-\$5 million

Indirect Costs: None

Application Deadline: Nov 20, 2020

Website: <https://www.masslifesciences.com/funding-programs/>

14. McKnight Scholar Awards, McKnight Foundation/McKnight Endowment Fund for Neuroscience

The Scholar Awards support young scientists who: hold an MD and/or PhD degree; have completed formal postdoctoral training; and demonstrate a commitment to neuroscience. The Endowment Fund especially seeks applicants working on problems that, if solved at the basic level, would have immediate and significant impact on clinically relevant issues.

Citizenship: United States

Award Amount: \$225,000 paid over 2 years

Indirect Costs: None

Application Deadline: Jan 4, 2021

Website: <https://www.mcknight.org/programs/the-mcknight-endowment-fund-for-neuroscience/scholar-awards/>

15. Technology Awards, McKnight Foundation/McKnight Endowment Fund for Neuroscience

Technological Innovations in Neuroscience Awards support scientists who work on novel and creative approaches to understanding brain function.

The program seeks to advance and enlarge the range of technologies available to the neurosciences. It does not support research based primarily on existing techniques.

The Endowment Fund is especially interested in how technology may be used or adapted to monitor, manipulate, analyze, or model brain function at any level, from the molecular to the entire organism. Technology may take any form, from biochemical tools to instruments to software and mathematical approaches. Because the program seeks to advance and enlarge the range of technologies available to the neurosciences, research based primarily on existing techniques will not be considered.

A goal of the Technological Innovations awards is to foster collaboration between the neurosciences and other disciplines; therefore, collaborative and cross-disciplinary applications are explicitly invited.

Eligibility requirements (partial list):

- Must hold full-time appointments at the rank of assistant professor or higher, e.g. associate professor or professor, at institutions within the United States. Scientists holding other titles such as research professor, adjunct professor, professor research track, visiting professor, or instructor are not eligible.
- Must be developing new techniques or applying techniques to neuroscience in new ways.

Citizenship: Unspecified

Award Amount: \$200,000 paid over 2 years

Indirect Costs: None

LOI Deadline: Dec 7, 2020

Proposal Deadline: Apr 26, 2021

Website: <https://www.mcknight.org/programs/the-mcknight-endowment-fund-for-neuroscience/technology-awards/>

16. Biosimilars in Hematologic Malignancies & Supportive Care, Pfizer Global Medical Grants (GMG) **NEW! COVID!**

The professional education goal of this RFP is to support the prudent (safe and effective) use of biologic drugs in patients with hematologic malignancies or for use in supportive care by:

- Increasing clinicians' understanding of complex biosimilar concepts including, the analytical foundation, clinical data analysis for biosimilars and global differences in the regulatory framework governing the approval of biosimilar drugs.
- Implementing practical approaches to the incorporation of biosimilars into hematology-oncology practice in all label indications, including protocols, guidelines and pathways. Including, improving the ability of healthcare professionals to discuss biosimilar options with their patients as part of shared-decision-making
- Discussing emerging RWE from biosimilars in hematologic malignancies and RWE data gaps preventing full utilization the health care utilization
- Discussing available data regarding Short- versus Long-Acting Granulocyte Colony-Stimulating Factors for Reduction of Chemotherapy-Induced Febrile Neutropenia
- Discuss the use of Granulocyte Colony-Stimulating Factors in the SARS-2 (covid19) era and the role of biosimilars to reduce hospital cost burden
- Overcoming global roadblocks to help realize the potential for cost-savings of biosimilars in hematologic malignancies and in supportive care and the overall benefit to reducing healthcare costs in society.

All CME/CE activity types will be considered through this RFP including but not limited to:

- Live or virtual national or regional symposia, workshops, regional community series; online courses & digital tools, handouts & other printed materials
- Activities for healthcare professionals that also include educational materials or resources for patients
- Applications from Professional Societies focused on providing education and/or tools to their members are of particular interest.

Citizenship: Unrestricted

Award Amount: \$200,000

Indirect Costs: 28%

Application Deadline: Nov 2, 2020

Website: <https://www.pfizer.com/purpose/independent-grants/competitive-grants>

17. Emerging Mechanisms of Action in the Treatment of Moderate-to-Severe Atopic Dermatitis, Pfizer Global Medical Grants (GMG) **NEW!**

Through this RFP, it is our intent to support education programs for dermatologists and allergists on new small molecule and biological based emerging therapies of moderate-to-severe atopic dermatitis, as well as the emerging mechanisms of action in the treatment of this disease.

It is not our intent to support clinical research projects.

Citizenship: Unrestricted

Award Amount: \$200,000

Indirect Costs: 28%

Application Deadline: Oct 15, 2020

Website: <https://www.pfizer.com/purpose/independent-grants/competitive-grants>

18. Identifying and Diagnosing polyarticular Juvenile Idiopathic Arthritis (pJIA), Pfizer Global Medical Grants (GMG)

Projects that will be considered for Pfizer support will focus on Healthcare Practitioners (HCPs) that may encounter and/or diagnose, refer, or treat pJIA. Educating the HCP community on pJIA will help to potentially reduce time in accurately identifying and diagnosing pediatric patients, which will improve patient outcomes.

It is not our intent to support clinical research projects.

Citizenship: Canada or United States

Award Amount: \$200,000

Indirect Costs: 28%

Application Deadline: Oct 23, 2020

Website: <https://www.pfizer.com/purpose/independent-grants/competitive-grants>

19. Research Grants, Terri Brodeur Breast Cancer Foundation (TBBCF)

The Foundation's Grant Program seeks to fund clinical and pre-clinical fellowships in high impact, breast cancer therapeutic research areas. This award is intended to support PhD, MD/PhD and MD physician scientists at earlier stages of their careers.

Citizenship: United States

Award Amount: \$100,000 paid over 2 years

Indirect Costs: None

Application Deadline: Nov 20, 2020

Website: <http://terribrodeurbreastcancerfoundation.org/granting-process/>